Medication info
Candesartan Plus Pro Tablet

Candesartan Plus Pro Tablet

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201007281 · Notified 2010.11.30 · Insurance code 657804520

Summary

Main use
Treatment of hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy : Treatment with individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start treatment with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose : Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose may be administered when creatinine clearance is 30 mL/min or higher. In patients with more severe renal impairment, loop diuretics are preferable to thiazide-type drugs; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment is 25 mg, which cannot be administered using this medicine; therefore, administration to these patients is not recommended.
Child dose
○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled by monotherapy

  • Hypertension
View approved original text

This medication is used as an adjunct therapy for patients with hypertension whose blood pressure is not adequately controlled by monotherapy. It helps effectively lower blood pressure, reduce the risk of complications, and improve overall cardiovascular health. Therefore, it is used for the treatment of hypertension.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg daily are not recommended. The maximum blood pressure-lowering effect generally occurs about 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy : Treatment with individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy : Start with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy : Start treatment with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure control at this dose : Treatment may be started with 1 tablet containing losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet containing losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose may be administered when creatinine clearance is 30 mL/min or higher. In patients with more severe renal impairment, loop diuretics are preferable to thiazide-type drugs; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment The initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment is 25 mg, which cannot be administered using this medicine; therefore, administration to these patients is not recommended.

Child dose

○ Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially during the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with certain diseases or those who have hypersensitivity to the medication. For example, patients with anuria, severe liver impairment, significantly reduced kidney function, and pregnant women may be at risk if they take this medication. Patients with significantly low blood pressure or kidney issues, systemic lupus erythematosus, and older adults should use caution when taking this medication, and they must strictly follow the physician’s instructions. While taking this medication, blood pressure, kidney function, electrolyte levels, etc., should be regularly monitored for any abnormalities, particularly paying attention to electrolyte imbalances such as hypokalemia or hyperkalemia. This medication may make the skin sensitive to sunlight, potentially increasing the risk of non-melanoma skin cancer; therefore, precautions against UV exposure and skin protection should be observed while taking it. Symptoms such as dizziness, drowsiness, headache, cough, and edema may occur; if severe symptoms appear, consult a doctor immediately. This medication may interact with other drugs; therefore, especially when taking potassium supplements, diuretics, antihypertensives, non-steroidal anti-inflammatory drugs, or lithium preparations, be sure to inform the physician. Women planning to become pregnant or those who are pregnant should consult healthcare professionals before taking this medication, and breastfeeding women are recommended to avoid taking it or to stop breastfeeding while on this medication. It is recommended not to use this medication in children or adolescents, as safety and efficacy have not been established. While taking this medication, caution is needed when driving or operating machinery, as dizziness or drowsiness may occur. In case of overdose, symptoms such as low blood pressure and arrhythmia may appear, and immediate medical attention should be sought.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 164 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin peeling
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary AV block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • lethargy
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscular rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory disturbance
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neurogenic sensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disturbances
  • drowsiness
  • tremors
  • dizziness
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flush
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste disturbances
  • tinnitus
  • erectile dysfunction
  • nocturnal enuresis
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • hemolytic anemia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle spasms
  • anxiety
  • renal failure
  • renal impairment
  • interstitial nephritis
  • mucocutaneous syndrome
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute closed-angle glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis
  • hypotension
  • tachycardia
  • hypokalemia
  • hypochloremia
  • hyponatremia
  • thirst
  • thirst
  • weakness
  • somnolence
  • drowsiness
  • anxiety
  • confusion
  • seizures
  • myalgia
  • muscle fatigue
  • reduced urine output
  • nausea
  • vomiting
  • arrhythmia
  • elevated serum creatinine level
  • angioedema
  • vasculitis
  • thrombocytopenia
  • angioedema
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to light; therefore, it should be stored in a container that blocks light. Additionally, it is important to maintain a room temperature of 1 to 30 degrees Celsius for storage. This ensures the efficacy and safety of the medication.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.